Optimising Cardiac Resynchronization Therapy With Device Algorithms

Cardiac resynchronization therapy has reshaped the management of heart failure with reduced ejection fraction and intraventricular conduction delay, yet a sizeable share of recipients remain non-responders despite apparently appropriate implantation. Optimising the timing of atrial and ventricular pacing after device implant has long been a labour-intensive process, typically requiring surface electrocardiography, echocardiography, and iterative reprogramming during repeated clinic visits. Device-based algorithms now automate much of this work, interrogating intracardiac electrograms, adjusting atrioventricular and interventricular intervals, and adapting to changes in heart rate, posture, and autonomic tone.

For Australian clinicians working across vast distances and varied health systems, these built-in tools have practical implications that extend beyond the consulting room. Whether a patient is reviewed at a tertiary centre in Sydney, a private practice in Perth, or a rural outreach clinic in western Queensland, the same implanted hardware can deliver reproducible, physiology-guided pacing without requiring the patient to travel hundreds of kilometres. The growing body of evidence behind adaptive algorithms, combined with reimbursement frameworks that recognise remote monitoring, is changing the way biventricular pacing is delivered and audited in this country.

From bedside empiricism to algorithmic precision

The earliest days of resynchronisation relied on Doppler echocardiography to fine-tune the atrioventricular delay, with operators aiming for separation of the E and A waves, truncation of isovolumic relaxation time, and improvements in the myocardial performance index. The approach was time-consuming, operator-dependent, and difficult to reproduce. As device memory expanded and algorithms became more sophisticated, manufacturers introduced automated searches for optimal intervals based on intrinsic conduction, evoked response, or impedance changes.

These algorithms generally fall into three families: those that measure intrinsic conduction and adjust pacing to promote fusion with native rhythm, those that use beat-to-beat haemodynamic surrogates such as right ventricular impedance, and those that rely on a combination of intracardiac electrogram morphology and template matching. Each has strengths and limitations, and the choice often depends on the patient's rhythm substrate, bundle branch block pattern, and the proportion of time spent in sinus rhythm versus atrial fibrillation.

For clinicians trained in the era of trial-and-error optimisation, the transition to letting software make routine timing decisions requires a degree of trust. That trust is built when the device is interrogated at follow-up and the histogram of delivered intervals correlates with the patient's symptoms, functional capacity, and structural response. The audit of these outcomes is increasingly a quality-of-care indicator in Australian heart failure services, particularly where multidisciplinary teams include advanced practice nurses, physiologists, and heart failure cardiologists.

Inside the device: how automated algorithms function

Modern devices use a combination of atrial sensing, right and left ventricular pacing, and continuous measurement of intracardiac signals to calculate the timing relationships that maximise ventricular synchrony. The simplest algorithms adjust the AV delay based on the PR interval, shortening or lengthening the paced and sensed values within a programmable range. More complex versions measure interventricular conduction time, compare the morphology of paced and intrinsic beats, and adapt to changes in rate and activity.

Some algorithms are particularly useful in patients with intermittent conduction disease. A patient with rate-dependent left bundle branch block, for example, may benefit from a mode that promotes intrinsic conduction at rest but switches to biventricular pacing when the block emerges. Others are designed for patients in atrial fibrillation, where AV node ablation combined with automated ventricular pacing algorithms can restore regularity and rate without repeated in-clinic reprogramming. The sophistication of these features varies between manufacturers, and Australian procurement committees must weigh performance claims against local cost, training requirements, and post-implant support.

Clinicians should also appreciate what the algorithm does not do. It does not adjust lead position, modify scar burden, or compensate for suboptimal coronary sinus anatomy. It cannot reverse a poor initial implant, and it cannot overcome the effects of an inappropriately programmed upper rate limit or a pacing polarity that captures the phrenic nerve. Recognising the limits of automation is essential to using it safely, especially when troubleshooting unexpected symptoms in the months after implant.

Clinical evidence and responder rates

Randomised trials of automated optimisation algorithms have produced mixed but generally favourable results compared with fixed delays or echocardiographic optimisation. Some algorithms, particularly those that maximise the patient's intrinsic conduction or use impedance-based haemodynamic feedback, have shown modest improvements in left ventricular ejection fraction, reductions in left ventricular end-systolic volume, and gains in six-minute walk distance over six to twelve months. Others have shown non-inferiority rather than superiority, but the practical value of reduced clinic time and reproducible timing remains.

What the trials often lack is long-term data on hard outcomes, particularly heart failure hospitalisation and mortality. Registry analyses from large European and North American centres suggest that consistent AV and VV optimisation is associated with better reverse remodelling, but causation is difficult to establish. The Australasian contribution to this literature has grown with participation in the ANZACS-QI registry and local investigator-initiated studies, though a dedicated Australian CRT registry linked to the Department of Health's data linkage services would clarify how algorithm choice interacts with outcomes in the real world.

Patient selection remains the single biggest determinant of response. Left bundle branch block with QRS duration above 150 milliseconds, non-ischaemic aetiology, and female sex continue to predict favourable reverse remodelling. Algorithms can refine the result, but they cannot rescue an implant performed in a patient unlikely to benefit. This reality has sharpened the focus on referral pathways within Australian health services, where general practitioners, general cardiologists, and heart failure specialists must work together to identify candidates before irreversible remodelling sets in.

Integrating algorithms with imaging and physiology

Echocardiography remains the cornerstone of pre-implant assessment and post-implant response evaluation, but its role in the routine optimisation of pacing intervals has diminished. Strain imaging, particularly global longitudinal strain and the timing of regional strain peaks, offers a more nuanced view of dyssynchrony than older M-mode and Doppler measures, and it can be used to identify patients in whom particular algorithm settings are likely to underperform. Cardiac magnetic resonance imaging, where available, adds information on scar burden and lead placement relative to the latest activating segment, but access is limited outside major tertiary centres such as the Royal Prince Alfred, The Alfred, and the Royal Brisbane and Women's Hospital.

Cardiac CT and coronary venous anatomy mapping have become increasingly important in procedural planning, particularly for patients with prior coronary artery bypass grafts or congenital venous anomalies. The integration of these pre-procedural images with the device's own intracardiac electrograms and impedance trends creates a rich dataset for individualised programming. Some Australian centres now use proprietary platforms that overlay the implant geometry on follow-up data, allowing physiologists to adjust pacing configurations in the context of the patient's own anatomy.

For patients undergoing upgrade from a conventional pacemaker or ICD, the picture is more complex. Existing leads may not be in the optimal position, and the additional burden of an LV lead can interact unfavourably with right ventricular pacing burden or atrial lead parameters. Automated algorithms can ease the transition by maintaining synchrony during the adaptation period, but they cannot substitute for careful consideration of the upgrade indication, the patient's life expectancy, and the cumulative device burden. Operators should be aware of the TGA's post-market surveillance expectations, particularly when newer lead technologies or generator platforms are deployed in patients with limited options for future extraction.

Australian practice realities and reimbursement

The Australian device market operates under a hybrid public-private model, with implantation funded through the Medicare Benefits Schedule, the Private Health Insurance Prostheses List, and state-based public hospital budgets. CRT-D and CRT-P devices appear on the Prostheses List with defined benefit amounts, and hospitals negotiate volume rebates with manufacturers. The Therapeutic Goods Administration evaluates new algorithms and software updates through the Australian Register of Therapeutic Goods, and significant changes to device behaviour may trigger a new conformity assessment. For clinicians, this regulatory environment provides assurance that marketed algorithms have been reviewed for safety, even if local reimbursement decisions lag behind technological change.

Clinical follow-up is partially funded through MBS items for pacemaker and ICD checks, with separate provisions for remote monitoring transmissions and in-person device interrogation. The distinction matters in practice: a remote transmission reviewed by a credentialed physiologist does not always attract the same rebate as a face-to-face consultation, and the business case for a remote monitoring programme must be built around the savings from avoided emergency department visits and unplanned hospital admissions rather than procedural income alone. Public hospitals absorb a disproportionate share of the cost, which has implications for equity of access in regions such as the Northern Territory, where Indigenous patients carry a higher burden of heart failure and have historically had lower rates of device therapy.

Workforce distribution is another constraint. Cardiac physiologists capable of advanced device interrogation are concentrated in metropolitan areas, and outreach services often rely on a small number of senior clinicians visiting regional centres. Device-based algorithms that reduce the need for hands-on reprogramming are particularly valuable in this context, although training pathways for physiologists and technicians need to keep pace with the technology. The Cardiac Society of Australia and New Zealand has published guidance on competency-based training, and major vendors offer local courses, but small private clinics can find it difficult to release staff for extended education.

Remote monitoring and the tyranny of distance

Australia's geography makes remote monitoring more than a convenience. For patients in remote Western Australia, the Kimberley, or far north Queensland, the alternative to a working remote monitoring system is a journey of more than a thousand kilometres, often involving multiple flights, for a routine device check. Continuous remote monitoring of lead parameters, battery voltage, arrhythmia burden, and algorithm performance has been available for over a decade, but its integration with resynchronisation algorithms is a more recent development. Devices can now report the proportion of time spent in biventricular pacing, the range of delivered AV and VV intervals, and any alerts triggered by changes in the patient's intrinsic rhythm.

When the data are integrated with the patient's symptoms, weight, and medication adherence, the picture becomes granular enough to allow early intervention. A drop in biventricular pacing percentage in a patient with persistent atrial fibrillation may prompt anticoagulation review, rate control adjustment, or consideration of AV node ablation. A widening of the optimal AV interval over several months may signal progression of interatrial conduction delay. These trends are difficult to detect in a once-yearly in-person check, and the value of continuous data grows with the complexity of the underlying disease.

The practical challenges include connectivity, cybersecurity, and the legal framework for clinical decision-making based on remotely transmitted data. The Australian Cyber Security Centre has published guidance on medical device security, and individual health services have developed local protocols for managing alerts after hours. Patient consent, documentation, and the responsibilities of the receiving clinician must be clearly defined, and the professional indemnity arrangements for physiologists and cardiologists reviewing remote data should be understood by all members of the care team.

Complications remain an important consideration. Infection, lead failure, and the need for extraction are well-recognised risks of any implanted cardiac electronic device, and the presence of an additional left ventricular lead does not change the fundamentals of aseptic technique and early recognition. The Journal of Arrhythmia maintains a detailed resource on device infection management that complements the programming-focused content of this article.

Emerging frontiers: AI, multipolar leads and personalised pacing

The next generation of resynchronisation optimisation is likely to combine device-based algorithms with cloud-based analytics and machine learning models trained on large international datasets. Early studies suggest that artificial intelligence can predict impending decompensation from subtle changes in heart rate variability, impedance, and patient-reported symptoms several days before a clinical event. Integration with wearable sensors, including patches and smartwatches, could allow continuous ambulatory assessment of activity tolerance, sleep position, and pulmonary congestion, closing the loop between device behaviour and patient experience.

Multipolar left ventricular leads allow non-invasive adjustment of pacing vectors, which can rescue capture thresholds, avoid phrenic nerve stimulation, and target regions of latest activation without reoperation. Combined with algorithms that automatically test multiple vectors and select the one with the best capture and threshold profile, multipolar technology has reduced the historical burden of surgical revision. Newer lead designs with smaller diameters and improved deliverability are also expanding the population of patients who can receive a transvenous LV lead, although the role of the coronary sinus in limiting access has not been eliminated.

Personalised pacing, in which the device learns the patient's individual haemodynamic response to different intervals and adapts accordingly, is the logical endpoint of this trajectory. Australian patients and clinicians have the infrastructure to participate in the pivotal trials that will define the next decade of therapy delivery. State-based clinical trial networks, university teaching hospitals, and the National Heart Foundation's research funding programmes provide a foundation, and the country's multicultural population offers an opportunity to examine algorithm performance across diverse cardiac phenotypes. Patients reviewing clinical terminology references before consenting to upgrades or generator changes can contribute meaningfully to that conversation, and the resources available through the Journal of Arrhythmia will continue to support that shared decision-making.